Great point Anders! Did their CEO’s who were “confident in their pipeline” apply AI to ALL the trials in their pipeline to look for variables and to help weed out the noise or false leads instead of leading investors on a wild goose chase (Axon comes to mind). Did the companies design their trials to fail, fast, saving money and false hopes by leading patients on for years offering no hope once the trial ended or did they allow OLE’s for ALL THEIR TRIALS TO DATE aaannnddd have overwhelming enrollment for THREE INDICATIONS with one drug? Did they also design them with highly powered predictions based on known biomarkers NOT FOR THE DISEASE but for their drug ........ pipeline? Did their Ceo’s exhibit confidence in their pipeline by going around the market and by designing, funding, and executing (brand new never designed or ran before in CNS) the trials, all the way up to a phase 3 in some cases, on their own merit attracting TOP talent in each prospective disease field?
If yes to 3 or more of these questions than we should all agree they exuded confidence conveying to shareholders “we got this!” If no is the answer to more than 3 than my guess is they were either ignorant or scared to KNOW the results, too fast where as they would be given less time to sell “another round of funding” into a pay to play rigged market.
Good to have answers to these questions to make sure we are keeping Anavex’s methods and confidence in their pipeline in context to all other previous and or current Ceo’s pipelines!
Tred
AI
Market Data 
Markets 
